Cargando…

Modulating the Blood–Brain Barrier: A Comprehensive Review

The highly secure blood–brain barrier (BBB) restricts drug access to the brain, limiting the molecular toolkit for treating central nervous system (CNS) diseases to small, lipophilic drugs. Development of a safe and effective BBB modulator would revolutionise the treatment of CNS diseases and future...

Descripción completa

Detalles Bibliográficos
Autores principales: Whelan, Rory, Hargaden, Grainne C., Knox, Andrew J. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8618722/
https://www.ncbi.nlm.nih.gov/pubmed/34834395
http://dx.doi.org/10.3390/pharmaceutics13111980
_version_ 1784604816330194944
author Whelan, Rory
Hargaden, Grainne C.
Knox, Andrew J. S.
author_facet Whelan, Rory
Hargaden, Grainne C.
Knox, Andrew J. S.
author_sort Whelan, Rory
collection PubMed
description The highly secure blood–brain barrier (BBB) restricts drug access to the brain, limiting the molecular toolkit for treating central nervous system (CNS) diseases to small, lipophilic drugs. Development of a safe and effective BBB modulator would revolutionise the treatment of CNS diseases and future drug development in the area. Naturally, the field has garnered a great deal of attention, leading to a vast and diverse range of BBB modulators. In this review, we summarise and compare the various classes of BBB modulators developed over the last five decades—their recent advancements, advantages and disadvantages, while providing some insight into their future as BBB modulators.
format Online
Article
Text
id pubmed-8618722
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86187222021-11-27 Modulating the Blood–Brain Barrier: A Comprehensive Review Whelan, Rory Hargaden, Grainne C. Knox, Andrew J. S. Pharmaceutics Review The highly secure blood–brain barrier (BBB) restricts drug access to the brain, limiting the molecular toolkit for treating central nervous system (CNS) diseases to small, lipophilic drugs. Development of a safe and effective BBB modulator would revolutionise the treatment of CNS diseases and future drug development in the area. Naturally, the field has garnered a great deal of attention, leading to a vast and diverse range of BBB modulators. In this review, we summarise and compare the various classes of BBB modulators developed over the last five decades—their recent advancements, advantages and disadvantages, while providing some insight into their future as BBB modulators. MDPI 2021-11-22 /pmc/articles/PMC8618722/ /pubmed/34834395 http://dx.doi.org/10.3390/pharmaceutics13111980 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Whelan, Rory
Hargaden, Grainne C.
Knox, Andrew J. S.
Modulating the Blood–Brain Barrier: A Comprehensive Review
title Modulating the Blood–Brain Barrier: A Comprehensive Review
title_full Modulating the Blood–Brain Barrier: A Comprehensive Review
title_fullStr Modulating the Blood–Brain Barrier: A Comprehensive Review
title_full_unstemmed Modulating the Blood–Brain Barrier: A Comprehensive Review
title_short Modulating the Blood–Brain Barrier: A Comprehensive Review
title_sort modulating the blood–brain barrier: a comprehensive review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8618722/
https://www.ncbi.nlm.nih.gov/pubmed/34834395
http://dx.doi.org/10.3390/pharmaceutics13111980
work_keys_str_mv AT whelanrory modulatingthebloodbrainbarrieracomprehensivereview
AT hargadengrainnec modulatingthebloodbrainbarrieracomprehensivereview
AT knoxandrewjs modulatingthebloodbrainbarrieracomprehensivereview